软组织肉瘤

Fletcher CD, Bridge JA, Hogendoorn PCW, et al., eds. WHO/IARC classification of tumours: World Health Organization classification of tumours of soft tissue and bone. 4th ed (Vol 5). Lyon, France: IARC Press; 2013.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma. December 2018 [internet publication].

• 全文

American Joint Committee on Cancer. Soft tissue sarcoma. In: Edge SB, Byrd DR, Compton CC, et al., eds. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010: 291-8.

1.  Pisters PW, Casper ES, Mann GN. Soft-tissue sarcomas. In: Pazdur R, Coia LR, Hoskins WJ, et al, eds. Cancer management: a multidisciplinary approach. 9th ed. Melville, NY: PRR Inc.; 2005:585-614.

2.  Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109.

• 全文
• 摘要

3.  Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300.

• 全文
• 摘要

4.  Pisters P. Staging and prognosis. In: Pollock RE, ed. American Cancer Society atlas of clinical oncology: soft tissue sarcomas. Hamilton, Ontario: BC Decker; 2002:80-8.

5.  Clark MA, Fisher C, Judson I, et al. Soft tissue sarcomas in adults. N Engl J Med. 2005 Aug 18;353(7):701-11.

• 摘要

6.  Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001 May 15;91(10):1914-26.

• 摘要

7.  Dileo P, Demetri GD. Update on new diagnostic and therapeutic approaches for sarcomas. Clin Adv Hematol Oncol. 2005 Oct;3(10):781-91.

• 摘要

8.  Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003 Jun;9(6):1941-56.

• 全文
• 摘要

9.  Fletcher CD, Gustafson P, Rydholm A, et al. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol. 2001 Jun 15;19(12):3045-50.

• 摘要

10.  Fletcher CD, Bridge JA, Hogendoorn PCW, et al., eds. WHO/IARC classification of tumours: World Health Organization classification of tumours of soft tissue and bone. 4th ed (Vol 5). Lyon, France: IARC Press; 2013.

11.  Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v198-203.

• 全文

12.  Alston RD, Rowan S, Eden TO, et al. Cancer incidence patterns by region and socioeconomic deprivation in teenagers and young adults in England. Br J Cancer. 2007 Jun 4;96(11):1760-6.

• 摘要

13.  Weihkopf T, Blettner M, Dantonello T, et al. Incidence and time trends of soft tissue sarcomas in German children 1985-2004: a report from the population-based German Childhood Cancer Registry. Eur J Cancer. 2008 Feb;44(3):432-40.

• 摘要

14.  Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66.

• 全文
• 摘要

15.  Pazdur R, Coia LR, Hoskins WJ, et al. Cancer management: a multidisciplinary approach. 9th ed. Melville, NY: PRR Inc.; 2005.

16.  National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma. December 2018 [internet publication].

• 全文

17.  Adigun IA, Rahman GA, Buhari MO, et al. Pattern of rhabdomyosarcoma in Nigerian children. J Natl Med Assoc. 2008 Aug;100(8):906-9.

• 摘要

18.  Mandong BM, Kidmas AT, Manasseh AN, et al. Epidemiology of soft tissue sarcomas in Jos, North Central Nigeria. Niger J Med. 2007 Jul-Sep;16(3):246-9.

• 摘要

19.  Bhurgri Y, Bhurgri H, Pervez S, et al. Epidemiology of soft tissue sarcomas in Karachi South, Pakistan (1995-7). Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):709-14.

• 摘要

20.  Sullivan RJ, Pantanowitz L, Casper C, et al. Epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis. 2008 Nov 1;47(9):1209-15.

• 全文
• 摘要

21.  Gonne E, Collignon J, Kurth W, et al. Angiosarcoma consecutive to chronic lymphoedema: a Stewart-Treves syndrome [in French]. Rev Med Liege. 2009 Jul-Aug;64(7-8):409-13.

• 摘要

22.  Bliek J, Gicquel C, Maas S, et al. Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS). J Pediatr. 2004 Dec;145(6):796-9.

• 摘要

23.  Berrington de Gonzalez A, Kutsenko A, Rajaraman P. Sarcoma risk after radiation exposure. Clin Sarcoma Res. 2012 Oct 4;2(1):18.

• 全文
• 摘要

24.  Santiago J, Muszlak M, Samson C, et al. Malignancy risk and Wiedemann-Beckwith syndrome: what follow-up to provide? [in French]. Arch Pediatr. 2008 Sep;15(9):1498-502.

• 摘要

25.  Chuang SC, Vecchia CL, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 2009 Dec 1;286(1):9-14.

• 摘要

26.  Litzky LA. Pulmonary sarcomatous tumors. Arch Pathol Lab Med. 2008 Jul;132(7):1104-17.

• 全文
• 摘要

27.  Krishnan B, Khanna G, Clohisy D. Gene translocations in musculoskeletal neoplasms. Clin Orthop Relat Res. 2008 Sep;466(9):2131-46.

• 摘要

28.  Katenkamp D, Katenkamp K. Modern morphological diagnosis and current classification of soft tissue sarcomas [in German]. Chirurg. 2009 Mar;80(3):186-93.

• 摘要

29.  American Joint Committee on Cancer. Soft tissue sarcoma. In: Edge SB, Byrd DR, Compton CC, et al., eds. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010: 291-8.

30.  Ghosh J, Bhowmick A, Baguneid M. Oncovascular surgery. Eur J Surg Oncol. 2011 Dec;37(12):1017-24.

• 摘要

31.  Mendenhall WM, Indelicato DJ, Scarborough MT, et al. The management of adult soft tissue sarcomas. Am J Clin Oncol. 2009 Aug;32(4):436-42.

• 摘要

32.  Choong PF, Petersen IA, Nascimento AG, et al. Is radiotherapy important for low-grade soft tissue sarcoma of the extremity? Clin Orthop Relat Res. 2001 Jun;(387):191-9.

• 摘要

33.  Bui-Nguyen B, Italiano A, Delva F, et al. Adjuvant chemotherapy of adults soft tissue sarcomas [in French]. Bull Cancer. 2010 Jun;97(6):673-8.

• 摘要

34.  Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008 Aug 1;113(3):573-81.

• 摘要

35.  Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012 Mar 10;30(8):850-6.

• 全文
• 摘要

36.  Woll PJ, Reichardt P, Le Cesne A, et al; EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012 Oct;13(10):1045-54.

• 摘要

37.  Italiano A, Delva F, Mathoulin-Pelissier S, et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol. 2010 Dec;21(12):2436-41.

• 全文
• 摘要

38.  European Medicines Agency. EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo. 26 April 2019 [internet publication].

• 全文

39.  US Food & Drug Administration. FDA grants accelerated approval to new treatment for advanced soft tissue sarcoma. 19 October 2016 [internet publication].

• 全文

40.  Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995 Jul;13(7):1537-45.

• 摘要

41.  Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993 Jul;11(7):1269-75.

• 摘要

42.  Borden EC, Amato DA, Edmonson JH, et al. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer. 1990 Sep 1;66(5):862-7

• 摘要

43.  Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014 Apr;15(4):415-23.

• 摘要

44.  van der Graaf WT, Blay JY, Chawla SP, et al; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-86.

• 摘要

45.  Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. 2016 Mar 10;34(8):786-93.

• 全文
• 摘要

46.  Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37.

• 摘要

47.  Van De Voorde L, Delrue L, van Eijkeren M, et al. Radiotherapy and surgery - an indispensable duo in the treatment of retroperitoneal sarcoma. Cancer. 2011 Oct 1;117(19):4355-64.

• 摘要

48.  Cohen MH, Johnson JR, Justice R, et al. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors. Oncologist. 2012;17(7):992-7.

• 全文
• 摘要

49.  Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012 Mar 28;307(12):1265-72.

• 全文
• 摘要

50.  Dasanu CA. Length of adjuvant imatinib therapy in GIST: weighing benefits, side effects and costs. J Oncol Pharm Pract. 2012 Sep;18(3):379-80.

• 摘要

51.  Pandey R, Kochar R. Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy. J Gastrointest Cancer. 2012 Dec;43(4):547-52.

• 摘要

52.  Blesius A, Cassier PA, Bertucci F, et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer. 2011 Feb 15;11:72.

• 全文
• 摘要

53.  Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15;347(7):472-80.

• 全文
• 摘要

54.  Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34.

• 摘要

55.  Blay JY, Adenis A, Ray-Coquard I, et al. Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour? Curr Opin Oncol. 2009 Jul;21(4):360-6.

• 摘要

56.  Cirocchi R, Farinella E, La Mura F, et al. Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review. Tumori. 2010 May-Jun;96(3):392-9.

• 摘要

57.  Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer. 2007 Apr;43(6):974-8.

• 摘要

58.  Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008 Nov 20;26(33):5360-7.

• 摘要

59.  Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010 Mar 1;28(7):1247-53.

• 摘要

60.  Cohen MH, Farrell A, Justice R, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Oncologist. 2009 Feb;14(2):174-80.

• 全文
• 摘要

61.  Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008 Feb 1;26(4):626-32.

• 摘要

62.  Cancer Care Ontario. Sunitinib malate for gastrointestinal stromal tumour (GIST) in imatinib mesylate-resistant patients. January 2014 [internet publication].

• 全文

63.  National Institute for Health and Care Excellence. Sunitinib for the treatment of gastrointestinal stromal tumours. September 2009 [internet publication].

• 全文

64.  Demetri GD, Garrett CR, Schöffski P, et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res. 2012 Jun 1;18(11):3170-9.

• 全文
• 摘要

65.  Reichardt P, Blay JY, Gelderblom H, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol. 2012 Jul;23(7):1680-7.

• 全文
• 摘要

66.  Demetri GD, Reichardt P, Kang YK, et al; GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):295-302.

• 全文
• 摘要

67.  Maurel J, Lopez-Pousa A, de Las Penas R, et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol. 2009 Apr 10;27(11):1893-8.

• 摘要

68.  Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997 Dec 6;350(9092):1647-54.

• 摘要

69.  Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol. 2007 Jul 20;25(21):3144-50.

• 全文
• 摘要

70.  Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 1;27(19):3133-40.

• 全文
• 摘要

71.  von Mehren M, Rankin C, Goldblum JR, et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012 Feb 1;118(3):770-6.

• 全文
• 摘要

72.  Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007 May 1;25(13):1753-9.

• 全文
• 摘要

73.  Verschraegen CF, Arias-Pulido H, Lee SJ, et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol. 2012 Mar;23(3):785-90.

• 全文
• 摘要

74.  Mir O, Boudou-Rouquette P, Larousserie F, et al. Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma. Anticancer Drugs. 2012 Aug;23(7):745-8.

• 摘要

75.  Hingorani P, Eshun F, White-Collins A, et al. Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas. J Pediatr Hematol Oncol. 2012 Oct;34(7):524-7.

• 摘要

76.  Cassier PA, Labidi-Galy SI, Heudel P, et al. Therapeutic pipeline for soft-tissue sarcoma. Expert Opin Pharmacother. 2011 Nov;12(16):2479-91.

• 摘要

77.  Chawla SP, Papai Z, Mukhametshina G, et al. First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized clinical trial. JAMA Oncol. 2015 Dec;1(9):1272-80.

• 全文
• 摘要

78.  Verma S, Younus J, Haynes AE, et al. Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a clinical practice guideline. Curr Oncol. 2008 Apr;15(2):80-4.

• 全文
• 摘要

79.  Verma S, Younus J, Stys-Norman D, et al. Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review. Cancer. 2008 Mar 15;112(6):1197-205.

• 全文
• 摘要

80.  Pacelli F, Tortorelli AP, Rosa F, et al. Retroperitoneal soft tissue sarcoma: prognostic factors and therapeutic approaches. Tumori. 2008 Jul-Aug;94(4):497-504.

• 摘要

81.  Koscielniak E, Morgan M, Treuner J. Soft tissue sarcoma in children: prognosis and management. Paediatr Drugs. 2002;4(1):21-8.

• 全文
• 摘要

82.  Sciot R, Debiec-Rychter M, Daugaard S, et al. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): an analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. Eur J Cancer. 2008 Sep;44(13):1855-60.

• 摘要

83.  Terenziani M, Piva L, Meazza C, et al. Oophoropexy: a relevant role in preservation of ovarian function after pelvic irradiation. Fertil Steril. 2009 Mar;91(3):935.e15-6.

• 摘要

84.  Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48(7):964-70.

• 摘要

85.  Fernebro J, Bladstrom A, Rydholm A, et al. Increased risk of malignancies in a population-based study of 818 soft-tissue sarcoma patients. Br J Cancer. 2006 Oct 23;95(8):986-90.

• 全文
• 摘要

86.  Puri A, Gulia A, Hawaldar R, et al. Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial. Clin Orthop Relat Res. 2014 May;472(5):1568-75.

• 摘要

87.  Kumar R, Chauhan A, Vellimana AK, et al. Role of PET/PET-CT in the management of sarcomas. Expert Rev Anticancer Ther. 2006 Aug;6(8):1241-50.

• 全文
• 摘要

88.  Treglia G, Salsano M, Stefanelli A, et al. Diagnostic accuracy of 18F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis. Skeletal Radiol. 2012 Mar;41(3):249-56.

• 摘要